← FDA Drug Approvals (Drugs@FDA)
EMPAGLIFLOZIN; LINAGLIPTIN
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: ALKEM LABS LTD · Approved 2022-08-09
Drug application
- FDA Application #
ANDA212366- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EMPAGLIFLOZIN; LINAGLIPTIN
- Generic name
- Empagliflozin
- Active ingredients
- EMPAGLIFLOZIN; LINAGLIPTIN
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- ALKEM LABS LTD
- First approval
- 2022-08-09
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown